Exploring immune responses in Hodgkin's lymphoma patients treated with pembrolizumab
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
This study is trying to see how the immune system of patients with relapsed Hodgkin's lymphoma responds to the treatment pembrolizumab to help improve future therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Drugs / interventions | Pembrolizumab |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06733987 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with relapsed or refractory classic Hodgkin Lymphoma who are being treated with pembrolizumab at the IRCCS AOU of Bologna. It involves collecting peripheral blood samples from participants before and during their treatment to analyze the immunological senescence phenotype. The study aims to understand how these immune characteristics may influence treatment resistance and patient outcomes. The findings could provide insights into optimizing therapy for Hodgkin's lymphoma patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with relapsed or refractory classic Hodgkin Lymphoma who are eligible for treatment with pembrolizumab.
Not a fit: Patients who are not candidates for pembrolizumab treatment or those with other forms of lymphoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify immune profiles that predict treatment responses, leading to more personalized and effective therapies for Hodgkin's lymphoma.
How similar studies have performed: While similar studies have explored immune responses in cancer treatments, this specific approach to analyzing immunological senescence in Hodgkin's lymphoma with pembrolizumab is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of both sexes aged ≥ 18 years at enrollment * Patients affected by cHL R/R candidate to receive a treatment with Pembrolizumab * Signature of informed consent Exclusion Criteria: * none
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero - Universitaria di Bologna — Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Pier Luigi Zinzani, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Pier Luigi Zinzani, MD
- Email: pierluigi.zinzani@unibo.it
- Phone: +390512144042
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.